TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01663922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir as Victrelis(r) 200mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir as Victrelis(r) 200mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St John's Wort
Description: Each Ucalm(r) tablet contains 300mg of St Johns Wort extract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St John's Wort
Description: Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
Study: NCT00834626

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ileal Interposition with Sleeve Gastrectomy
Description: Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
Study: NCT01069653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
Study: NCT03940703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants were administered with Tepotinib orally once daily at a dose of 500 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants were administered with Tepotinib orally once daily at a dose of 500 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Participants received Osimertinib at a dose of 80 mg orally once daily.
Study: NCT01385852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microcoaxial phacoemulsification
Description: conventional longitudinal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microcoaxial phacoemulsification
Description: conventional longitudinal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microcoaxial phacoemulsification
Description: conventional longitudinal ultrasound
Study: NCT04795765

Intervention type: PROCEDURE
Intervention: SpineJack system
Description: For use in the reduction of painful osteoporotic vertebral compression fractures.

Intervention type: PROCEDURE
Intervention: Balloon kyphoplasty
Description: Treatment of osteoporotic vertebral compression fractures.

Intervention type: PROCEDURE
Intervention: Vertebroplasty
Description: Treatment of osteoporotic vertebral compression fractures.
Study: NCT03309540

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study: NCT03806881

Intervention type: DEVICE
Intervention: reversed glenoid prothesis
Description: All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
Study: NCT00858377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Escalation
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Expansion
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Study: NCT03917056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy using long needle
Description: Participants were treated with CAES using long needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy using short needle
Description: Participants were treated with CAES using short needle.
Study: NCT04611009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor training
Description: In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness exercises
Description: The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
Study: NCT02590900

Intervention type: DRUG
Intervention: intravenous paracetamol (acetaminophen)
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.

Intervention type: DRUG
Intervention: intravenous paracetamol (acetaminophen)
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.

Intervention type: DRUG
Intervention: intravenous paracetamol (acetaminophen)
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
Study: NCT02013921

Intervention type: OTHER
Intervention: Physical activity
Study: NCT03936569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed Toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marketed Cavity Protection Toothpaste
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study: NCT02037672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and roflumilast
Study: NCT03698292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Prokinetic Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Prokinetic Drug
Study: NCT03021746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Support (DSMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Support (DSMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Support (DSMS)
Study: NCT02491138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appearance-based intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlets
Study: NCT03427710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to CiVi007
Study: NCT01768325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-TCB needle (QuickCore) standard of care
Description: * The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Guided biopsy needle (ProCore)
Description: * The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications
Study: NCT01288313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
Study: NCT00170209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
Study: NCT00325741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: 1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
Study: NCT00264147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Study: NCT01208389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec-rzyl
Description: One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
Study: NCT04020185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor (ICI)
Description: Administered according to product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor (ICI)
Description: Administered according to product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-oncology (IO) therapy
Description: Administered according to product label
Study: NCT02562443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any approved or standard-of-care therapy
Description: Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best supportive care (BSC)
Description: Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: best supportive care (BSC)
Description: Patients will receive best supportive care (BSC).
Study: NCT04845204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Treatment
Description: Relaxation Group recieve progressive muscle relaxation exercises additional to the standard exercises. The relaxation exercises are applied two times a day till the discharge day starting on the postoperative day one. Progressive muscle relaxation included the relaxing of different muscle groups along with deep breathing. The maximal contraction period consist of the contraction of muscle groups around ankle, calf, knee, hip, lumbar, thoracic and cervical regions, shoulder, arm, forearm for 5 s and continued with a relaxation period for 30 s while focusing on breathing. These two periods ware repeated for each muscle groups and lasted approximately 30 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercises
Description: The physiotherapy protocol is applied under the supervision of the same physiotherapist within a progressive manner immediately after surgery. Continued passive range of motion is applied twice a day starting with 45º of knee flexion range of motion and increased gradually as tolerated. All patients performed same isometric, isotonic and active exercises. Patients were instructed to bear weight as tolerated on the postoperative day 1
Study: NCT04101253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new screening procedure with small variations in electrode positioning
Description: Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist.
Study: NCT01638429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Neomycin: 500mg po bid for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin: 550mg po tid for 10 days
Study: NCT03823573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk within 24 hours
Description: Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk within 24 hours
Description: Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
Study: NCT01194375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Strength IDP-107
Description: Once a day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-107
Description: Once a day for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day for 16 weeks
Study: NCT00588978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and/or exercise
Description: Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and/or exercise
Description: Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and/or exercise
Description: Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
Study: NCT01828489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 1 mitoxantrone versus DaunoXome
Description: In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 1 mitoxantrone versus DaunoXome
Description: In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation course 1 mitoxantrone versus DaunoXome
Description: In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 2 ADxE versus FLADx
Description: The second course is randomised to either ADxE (standard arm) or FLADx

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation course 2 ADxE versus FLADx
Description: The second course is randomised to either ADxE (standard arm) or FLADx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 2 ADxE versus FLADx
Description: The second course is randomised to either ADxE (standard arm) or FLADx
Study: NCT03293459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shunt Occlusion
Description: Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment (SMT)
Description: These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment (SMT)
Description: These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin